LIQUISPHERE

Serial Number 97047897
807

Registration Progress

Application Filed
Sep 27, 2021
Under Examination
May 31, 2022
Approved for Publication
Apr 5, 2022
Published for Opposition
Apr 5, 2022
Registered

Attorney Assistance

Non-Final Action Mailed
Due: Sep 26, 2025 80 days

Basic Information

Serial Number
97047897
Deadline
September 26, 2025
Description
Respond to Non-Final Office Action - SOU
Filing Date
September 27, 2021
Published for Opposition
April 5, 2022
Drawing Code
4

Status Summary

Current Status
Active
Status Code
807
Status Date
Jun 26, 2025
Application
Pending
Classes
005

Rights Holder

Contract Pharmacal Corp.

03
Address
165 Oser Ave.
Hauppauge, NY 11788

Ownership History

Contract Pharmacal Corp.

Original Applicant
03
Hauppauge, NY

Contract Pharmacal Corp.

Owner at Publication
03
Hauppauge, NY

Legal Representation

Attorney
Seth A. Rappaport

USPTO Deadlines

Next Deadline
80 days remaining
Non-Final Action Mailed
Due Date
September 26, 2025
Extension Available
Until December 26, 2025
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

39 events
Date Code Type Description
Jun 26, 2025 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 26, 2025 GNRT O NON-FINAL ACTION E-MAILED
Jun 26, 2025 CNRT W SU - NON-FINAL ACTION - WRITTEN
Jun 12, 2025 SUPC I STATEMENT OF USE PROCESSING COMPLETE
May 30, 2025 EISU I TEAS STATEMENT OF USE RECEIVED
May 30, 2025 IUAF S USE AMENDMENT FILED
Jan 30, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 29, 2025 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jan 29, 2025 EX5G S SOU EXTENSION 5 GRANTED
Nov 15, 2024 EEXT I SOU TEAS EXTENSION RECEIVED
Nov 15, 2024 EXT5 S SOU EXTENSION 5 FILED
May 3, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 2, 2024 EXT4 S SOU EXTENSION 4 FILED
May 2, 2024 EEXT I SOU TEAS EXTENSION RECEIVED
May 2, 2024 EX4G S SOU EXTENSION 4 GRANTED
Nov 16, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 14, 2023 EX3G S SOU EXTENSION 3 GRANTED
Nov 14, 2023 EXT3 S SOU EXTENSION 3 FILED
Nov 14, 2023 EEXT I SOU TEAS EXTENSION RECEIVED
May 11, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 9, 2023 EX2G S SOU EXTENSION 2 GRANTED
May 9, 2023 EXT2 S SOU EXTENSION 2 FILED
May 9, 2023 EEXT I SOU TEAS EXTENSION RECEIVED
Dec 1, 2022 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 29, 2022 EX1G S SOU EXTENSION 1 GRANTED
Nov 29, 2022 EXT1 S SOU EXTENSION 1 FILED
Nov 29, 2022 EEXT I SOU TEAS EXTENSION RECEIVED
May 31, 2022 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Apr 5, 2022 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 5, 2022 PUBO A PUBLISHED FOR OPPOSITION
Mar 16, 2022 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 2, 2022 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 22, 2022 XAEC I EXAMINER'S AMENDMENT ENTERED
Feb 22, 2022 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Feb 22, 2022 GNEA F EXAMINERS AMENDMENT E-MAILED
Feb 22, 2022 CNEA R EXAMINERS AMENDMENT -WRITTEN
Feb 8, 2022 DOCK D ASSIGNED TO EXAMINER
Oct 27, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 30, 2021 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 005
Drug delivery agents in the form of powders, liquids, creams, gels, and pastes that facilitate the delivery of therapeutic agents and pharmaceutical preparations; Drug delivery agents in the form of powders, liquids, creams, gels, and pastes that provide controlled release of the active ingredients for a wide variety of therapeutics and pharmaceuticals; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of therapeutics and pharmaceuticals; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based powders, liquids, creams, gels, and pastes for the continuous release of a wide variety of therapeutic and pharmaceutical agents
First Use Anywhere: May 28, 2025
First Use in Commerce: May 28, 2025

Classification

International Classes
005